British Smaller Companies Fund

Total Page:16

File Type:pdf, Size:1020Kb

British Smaller Companies Fund BAILLIE GIFFORD Baillie Gifford British Smaller Companies Fund Quarterly Update 30 June 2021 This document has been prepared for use by professional advisers and intermediaries only. It is not intended for use by retail clients. This document contains information on investments which does not constitute independent investment research. Accordingly, it is not subject to the protections afforded to independent research and Baillie Gifford and its staff may have dealt in the investments concerned. Investment markets and conditions can change rapidly and as such the views expressed should not be taken as statements of fact nor should reliance be placed on these views when making investment decisions. This document is issued by Baillie Gifford & Co Limited, Calton Square, 1 Greenside Row, Edinburgh EH1 3AN, a company which is authorised and regulated by the Financial Conduct Authority, Financial Services Register No. 119179, and is a member of The Investment Association. Baillie Gifford & Co Limited is wholly owned by Baillie Gifford & Co, which is authorised and regulated by the Financial Conduct Authority. The Fund’s share price can be volatile due to movements in the prices of the underlying holdings and the basis on which the Fund is priced. As with any investment, the clients’ capital is at risk. Past performance is not a guide to future returns. All information as at 30 June 2021 and source is Baillie Gifford & Co unless otherwise stated. Baillie Gifford & Co Limited Calton Square, 1 Greenside Row, Edinburgh EH1 3AN Telephone +44 (0)131 275 2000 bailliegifford.com Copyright © Baillie Gifford & Co 2009 Ref: 53243 INT QR 0008 Executive Summary 01 Fund Objective To outperform (after deduction of costs) the Numis Smaller Companies Index (excluding Investment Companies) by at least 2% per annum over rolling five-year periods. The manager believes this is an appropriate target given the investment policy of the Fund and the approach taken by the manager when investing. In addition, the manager believes an appropriate performance comparison for this Fund is the Investment Association UK Smaller Companies Sector. There is no guarantee that this objective will be achieved over any time period and actual investment returns may differ from this objective, particularly over shorter time periods. Risk Analysis Key Statistics Number of Holdings 65 Typical Number of Holdings 50-80 Active Share 94%* Annual Turnover 8% *Relative to Numis Smaller Companies Index (ex. Inv.Companies).. Source: Baillie Gifford & Co, Numis. The fund is down, in relative terms, over the quarter and one year. Our process targets smaller companies trying to do novel things, which by default will be volatile We remain confident that the portfolio contains a collection of the very best British smaller companies. We firmly believe that over a multi-year timeframe it's these high quality, ambitious businesses that succeed and offer truly outsized returns We've taken positions in three new companies over the period - PensionBee, Oxford Biomedica and Essensys Commentary 02 The blocks to scale and the blocks of scale As a firm we owe W. Brian Arthur a huge debt of gratitude for his ideas on increasing returns to scale. “The value of a technology lies not merely But his writing on the Nature of Technology is also a in what can be done with it but also in what fantastic commentary on these tools of scale. Technology is recursive, as it consists of combinations of other further possibilities it will lead to.” technology. To borrow his example, a jet engine is built W BRIAN ARTHUR on compressors, turbines, combustion systems, all technologies in their own right with multiple applications. That means “technologies somehow must come into being as fresh combinations of what already In our commentary last quarter, we spent some time laying exists”. He describes this as combinatorial evolution, and out the remarkable role of technology and innovation in its power lies in having exponential potential. Each new lowering the barriers for would-be entrepreneurs starting component is capable of building on the components that new businesses. From the internet to the iPhone, the global came before to create new components for what comes tech ecosystem is increasingly providing building blocks after. “The more there is to invent with, the greater will that today empower small companies to innovate quickly be the number of inventions.” and reach the right customers affordably as never before. The portfolio includes a wide range of remarkable British businesses both helping create these blocks, and benefiting from them. The obvious follow up question however is what comes next? It’s great that today a start-up that 50 years ago may have quickly failed can emerge and thrive, but for us as long-term investors, often the most important question is how can that start-up take its early success and turn it into longer-term sustainable growth? This question is at the heart of our recent thinking around the scalability of smaller companies, indeed scalability is one of the core components of our research process. If we get it right it should be one of the superpowers of smaller companies and one of the most plausible ways we can form views that are differentiated from the market as a source of Insight. Often scalability means talking to companies about the bottlenecks they face in growing into their opportunity. Some of those challenges differ across the portfolio – for Victoria it’s finding attractive acquisitions, for Creo Medical it’s training doctors, for Fevertree, international distribution – but many will be common. An obvious example here is the challenge of recruiting and assimilating people quickly and effectively. These The likelihood is evidence of accelerating constraints are the reason why businesses traditionally combinatorial evolution lies within those business grew slower as they got larger, an important dynamic for formation trends. Companies are a form of technology us to understand. But we’re finding those building blocks and they too are increasingly recursive. Companies build are increasingly shifting the balance of power from on companies. DotDigital within our own portfolio scalability constraints towards accelerants. It means more demonstrates this in action. Dot builds on existing time focused on the opportunities rather than the technologies like email, SMS or WhatsApp to let challenges of growth, a source of immense optimism businesseses communicate with their customers. That about the future. As an entrepreneur’s toolkit expands so communication is only one function a modern business does her possibilities and potential. needs, and so Dot itself becomes a block on which other businesses are built. It is ready to plug and play, abstracting away a huge amount of complexity for its enterprise customers. Another good example of these building blocks within the portfolio would be Clipper Logistics. The business combines broader advancements in logistics and robotics to provide a platform for Commentary 03 businesses looking for warehousing and delivery Portfolio commentary infrastructure. One of the pleasurable challenges for us in thinking about scalability is the endless possibilities our As ever, I will start by emphasising that we do not young, dynamic businesses have to combine technologies believe three months is a meaningful amount of time over to meet new needs. which to judge an underlying business’s performance. This positive aspect of scalability – the combinatorial As bottom-up, fundamental growth investors our job is to possibilities of a modern entrepreneur’s toolkit – is discover a small handful of exceptional businesses that transforming the possibilities for smaller companies to have strong multi-year prospects. If three months is form, grow and succeed rapidly. It took Trustpilot only uninformative in measuring multi-year success for any seven years from opening its first UK office for it to win one of those underlying businesses, then in turn we don’t 14 per cent of all eligible UK businesses as customers. think it will be particularly informative as a measure of But there is something more to the scalability advantage portfolio performance. We’d urge you to look five years of smaller companies than merely size. It is about and beyond, and I’d go as far as saying that if stable attitude, culture and the drive to survive. The venture quarterly-on-quarter returns are what matter to you, we’re capitalist and teacher Jerry Neumann suggests combining unlikely to ever offer you the smooth progress you are technologies to serve new needs or wants means looking for. Small companies trying to do dramatic, confronting uncertainty. New wants are new markets and novel things will almost by default remain volatile, as it is highly uncertain that customers will be interested. will market sentiment towards them. What we firmly That uncertainty is a challenge for large existing believe however is that over a multi-year timeframe it’s businesses, for the behavioural and organisational reasons those ambitious, risk tolerant businesses that succeed, that I think we all recognise, leaving the space open for which may offer truly outsized returns. younger, nimbler, more entrepreneurial companies like This is not to say exciting noteworthy things don’t those in the portfolio. One of our more recent holdings sometimes happen in a quarter. The past three months PensionBee has designed tools that allows users to find saw several such events. Notable progress was made by and merge all their legacy pension pots into one Victoria in its ongoing large-scale flooring company roll- transparent, easy to manage online platform. The UK up with notable acquisitions in the Netherlands and the pension market is currently undergoing significant US. This quarter also saw liquid biopsy specialist Angle change. There is simultaneously a switch from direct launch its initial clinical laboratory, and quickly secured benefit to direct contribution saving, and a growth in the first large-scale pharmaceutical client for its young people changing jobs more frequently throughout proprietary blood-testing service.
Recommended publications
  • Jefferies 2013 Global Healthcare Conference in London
    Jefferies 2013 Global Healthcare Conference in London At the 2012 Jefferies Global Healthcare Conference, there were well over 200 healthcare companies participating with a combined market cap of $1 trillion and close to 1,300 one-on-one/small group meetings over the two-day event. The 2013 conference is set to follow the same footsteps, featuring public and private leading INVITATION global healthcare companies within the areas of pharmaceuticals, biotech, generics, 20-21 NOVEMBER 2013 medtech and healthcare services from the US, Central and Eastern Europe, Latin The Waldorf Hilton America, India, China, Japan, Egypt, Israel and Russia. London, UK Throughout the two-day event, we will feature concurrent tracks of informative presentations as well as 1x1/small group meetings, and thematic panel discussions. This global gathering of institutional investors, private equity investors, VCs and leading executives will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare. We hope you can join us for what promises to be a unique and comprehensive view of the industry. Registration is now open. Please email your Jefferies representative if you are interested in attending. For general questions, please email [email protected] or contact your Jefferies representative. © 2013 Jefferies LLC. Member SIPC. AGENDA WEDNESDAY, 20 NOVEMBER 2013 Jefferies 2013 Global Healthcare Conference in London ADELPHI 1 ADELPHI 2 ADELPHI 3 EXECUTIVE BOARDROOM 7:30 AM Breakfast & Registration 8:00 AM Clinigen Group Plc Ion Beam Applications Active Biotech AB Syneron Medical Ltd. Specialty Pharma & Healthcare Services Medical Products Biotechnology Medical Technology Paul Thomas; CTO Olivier Legrain, CEO Tomas Leanderson; President and CEO Hugo Goldman, CFO 8:40 AM Valneva Celltrion, Inc.
    [Show full text]
  • March 2018 1 MARKET UPDATE| HEALTHCARE
    MARKET UPDATE| HEALTHCARE MARKET UPDATE HEALTHCARE March 2018 1 MARKET UPDATE| HEALTHCARE HIGHLIGHTS Dear Reader, 2017 ended with the $69 billion CVS Health / Aetna deal. Pharmacy +6.5% Benefit Manager (PBM) consolidation took another major step this month 5Y-CAGR with Cigna scooping up the largest independent PBM, Express Scripts, in a $52 billion deal. Additionally, rumor has it that Walmart is in the early Worldwide stages talks with insurer Humana, looking at a variety of options including prescription drugs - an acquisition. The frenzy might very well be due to Amazon’s debut in expected sales healthcare and the looming shadow of its entrance in the pharmacy market. But Amazon is also putting pressure on consumer care products, intensifying price competition. In response, pharmaceuticals groups are +5.3% parted between those which want to hold on to these products that are 5Y-CAGR generally durable brands with loyal customers, and others which doubt Medtech market - their long-term stable returns. GlaxoSmithKline had us hold our breath: expected growth after entering - and eventually quitting - the race to buy Pfizer’s consumer healthcare business for a price tag hoped to be as much as $20 billion, the company bought Novartis out of their consumer healthcare joint venture for $13 billion. GSK is thus taking full control of products -0.7%/-2.2% including Sensodyne toothpaste, Panadol headache tablets and muscle gel Monthly EU Pharma & Voltaren. biotech performance March was also home to remarkable market transactions in the biotech and medtech fields that had us quite excited, beyond the fact that Bryan, Garnier & Co.
    [Show full text]
  • RCP BIA 2020 Review January 2021 FINAL.Pdf
    UK BioIndustry Association UK Listed Biotech & Life Sciences 2020 – Year in Review– May you live in interesting times Radnor Broad UK Listed Biotech Index - 2 Year Chart Unweighted Weighted FTSE All-Share 350 300 250 200 150 100 50 Dec '20 Dec Dec '18 Dec '19 Mar '19 Jun '19 Sep '19 Dec '20 Mar '20 Jun '20 Sep Source: FactSet, Radnor 2020 has been an extraordinary year across the market but there is no doubt that the UK listed biotech sector has been in the front line in more ways than one. Investors have clearly responded to both the efforts made by the sector to combat the pandemic, but also the structural growth opportunity within biotech that the pandemic has bought into sharper focus. Not only have we seen headline share price underperformance reverse sharply through the course of 2020, but critically, the pace and scale of sector fundraising activity has stepped up materially. Perhaps most importantly, the number of investors active in the sector (institutional, private wealth, individual and overseas) have expanded. This feature alone has gone a long way towards addressing one of the key issues facing the sector. The BioIndustry Association ▪ Sector Outperformance. 2020 has been the strongest period of price is a research client of Radnor outperformance over the last 10 years. Interestingly, this outperformance has Capital Partners Ltd. been delivered across all the sub-indices making up the Broad Biotech index; although performance levels have varied somewhat. This outperformance has MiFID II – this research is also been much more pronounced then looking at the sector on an equal deemed to be a minor, non- monetary benefit.
    [Show full text]
  • Global Equity Fund Description Plan 3S DCP & JRA MICROSOFT CORP
    Global Equity Fund June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA MICROSOFT CORP 2.5289% 2.5289% APPLE INC 2.4756% 2.4756% AMAZON COM INC 1.9411% 1.9411% FACEBOOK CLASS A INC 0.9048% 0.9048% ALPHABET INC CLASS A 0.7033% 0.7033% ALPHABET INC CLASS C 0.6978% 0.6978% ALIBABA GROUP HOLDING ADR REPRESEN 0.6724% 0.6724% JOHNSON & JOHNSON 0.6151% 0.6151% TENCENT HOLDINGS LTD 0.6124% 0.6124% BERKSHIRE HATHAWAY INC CLASS B 0.5765% 0.5765% NESTLE SA 0.5428% 0.5428% VISA INC CLASS A 0.5408% 0.5408% PROCTER & GAMBLE 0.4838% 0.4838% JPMORGAN CHASE & CO 0.4730% 0.4730% UNITEDHEALTH GROUP INC 0.4619% 0.4619% ISHARES RUSSELL 3000 ETF 0.4525% 0.4525% HOME DEPOT INC 0.4463% 0.4463% TAIWAN SEMICONDUCTOR MANUFACTURING 0.4337% 0.4337% MASTERCARD INC CLASS A 0.4325% 0.4325% INTEL CORPORATION CORP 0.4207% 0.4207% SHORT-TERM INVESTMENT FUND 0.4158% 0.4158% ROCHE HOLDING PAR AG 0.4017% 0.4017% VERIZON COMMUNICATIONS INC 0.3792% 0.3792% NVIDIA CORP 0.3721% 0.3721% AT&T INC 0.3583% 0.3583% SAMSUNG ELECTRONICS LTD 0.3483% 0.3483% ADOBE INC 0.3473% 0.3473% PAYPAL HOLDINGS INC 0.3395% 0.3395% WALT DISNEY 0.3342% 0.3342% CISCO SYSTEMS INC 0.3283% 0.3283% MERCK & CO INC 0.3242% 0.3242% NETFLIX INC 0.3213% 0.3213% EXXON MOBIL CORP 0.3138% 0.3138% NOVARTIS AG 0.3084% 0.3084% BANK OF AMERICA CORP 0.3046% 0.3046% PEPSICO INC 0.3036% 0.3036% PFIZER INC 0.3020% 0.3020% COMCAST CORP CLASS A 0.2929% 0.2929% COCA-COLA 0.2872% 0.2872% ABBVIE INC 0.2870% 0.2870% CHEVRON CORP 0.2767% 0.2767% WALMART INC 0.2767%
    [Show full text]
  • Oxford Biomedica Delivering Commercial Gene-Therapy Vector
    31st March 2017 Pharmaceuticals & Biotechnology Oxford BioMedica Delivering commercial gene-therapy vector OXB is a specialist gene and cell therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, whilst retaining its own proprietary therapeutic candidates. Above service-fees, OXB will receive royalties Source: Fidessa on commercial products developed with its LentiVector® platform: extensive IP, facilities, and know-how for production and development of lentiviral vectors to Market data generate gene-based therapies. OXB intends to out-license its five clinical EPIC/TKR OXB candidates and to continue investment in R&D. Bioprocessing royalties are likely Price (p) 5.2 to result in significant upside potential in the near future. 12m High (p) 6.5 12m Low (p) 3.0 ► Strategy: Oxford BioMedica has four strategic objectives: delivery of process Shares (m) 3,088.2 development services which embed its technology in partners’ commercial Mkt Cap (£m) 159.0 products; commercial manufacture of lentiviral vector; out-licensing of EV (£m) 178.1 proprietary candidates; and investment in R&D and the LentiVector platform. Free Float 65% Market LSE ► Revenues: Bioprocessing and process development command fees-for-service, with process development also incurring upfront, milestone and incentive Description payments plus licensing income and royalties on commercial products. Out- Oxford BioMedica is a UK-based licensed candidates will deliver licensing fees plus high royalties if successful. biopharmaceutical company specializing in cell and gene therapies developed using lentiviral vectors, ► Valuation: An EV/sales multiple of 4x prospective sales for the bioprocessing gene-delivery vehicles based on virus and process development services is readily justified, which generates a value particles.
    [Show full text]
  • FTSE Russell Publications
    2 FTSE Russell Publications 19 August 2021 FTSE 250 Indicative Index Weight Data as at Closing on 30 June 2021 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) 3i Infrastructure 0.43 UNITED Bytes Technology Group 0.23 UNITED Edinburgh Investment Trust 0.25 UNITED KINGDOM KINGDOM KINGDOM 4imprint Group 0.18 UNITED C&C Group 0.23 UNITED Edinburgh Worldwide Inv Tst 0.35 UNITED KINGDOM KINGDOM KINGDOM 888 Holdings 0.25 UNITED Cairn Energy 0.17 UNITED Electrocomponents 1.18 UNITED KINGDOM KINGDOM KINGDOM Aberforth Smaller Companies Tst 0.33 UNITED Caledonia Investments 0.25 UNITED Elementis 0.21 UNITED KINGDOM KINGDOM KINGDOM Aggreko 0.51 UNITED Capita 0.15 UNITED Energean 0.21 UNITED KINGDOM KINGDOM KINGDOM Airtel Africa 0.19 UNITED Capital & Counties Properties 0.29 UNITED Essentra 0.23 UNITED KINGDOM KINGDOM KINGDOM AJ Bell 0.31 UNITED Carnival 0.54 UNITED Euromoney Institutional Investor 0.26 UNITED KINGDOM KINGDOM KINGDOM Alliance Trust 0.77 UNITED Centamin 0.27 UNITED European Opportunities Trust 0.19 UNITED KINGDOM KINGDOM KINGDOM Allianz Technology Trust 0.31 UNITED Centrica 0.74 UNITED F&C Investment Trust 1.1 UNITED KINGDOM KINGDOM KINGDOM AO World 0.18 UNITED Chemring Group 0.2 UNITED FDM Group Holdings 0.21 UNITED KINGDOM KINGDOM KINGDOM Apax Global Alpha 0.17 UNITED Chrysalis Investments 0.33 UNITED Ferrexpo 0.3 UNITED KINGDOM KINGDOM KINGDOM Ascential 0.4 UNITED Cineworld Group 0.19 UNITED Fidelity China Special Situations 0.35 UNITED KINGDOM KINGDOM KINGDOM Ashmore
    [Show full text]
  • Witan Investment Trust Plc Portfolio Listing As at 31.07.2021
    WITAN INVESTMENT TRUST PLC PORTFOLIO LISTING AS AT 31.07.2021 SECURITY % OF TOTAL INVESTMENT APAX GBL ALPHA NPV 2.98 ALPHABET A USD0.001 1.88 PRINCESS PRIVATE EQTY HLDGS ORD EUR0.001 1.87 ELECTRA PRIVATE GBP 0.25 1.53 SYNCONA ORD NPV 1.34 CHARTER COMMUNICATIONS -A USD0.001 1.32 BLACKROCK WORLD MINING TST ORD GBP0.05 1.31 ARCELORMITTAL NPV 1.30 DIAGEO GBP28.93518 1.27 PAYPAL HLDGS USD0.0001 1.16 INTUIT USD0.01 1.11 HEINEKEN HLDGS EUR1.6 1.08 SCHRODER REAL ESTATE INV TST ORD NPV 1.03 THERMO FISHER SCIENTIFIC USD1 1.02 UNILEVER GBP0.031111 1.00 BT GRP ORD GBP0.05 0.98 NATWEST GRP GBP1 0.91 TAIWAN SEMICONDUCTOR MANUFACTURING 1 ADS REP 5 ORD TWD10 0.89 FACEBOOK A USD0.000006 0.89 FREEPORT-MCMORAN USD0.1 0.89 RELX GBP0.144397 0.86 NATL GRID ORD GBP0.12431289 0.85 LLOYDS BANKING GRP GBP0.1 0.85 VIVENDI EUR5.5 0.82 WALT DISNEY CO USD0.01 0.82 LINDENWOOD USD 0.81 BAE SYSTEMS ORD GBP0.025 0.80 MICROSOFT CORP USD0.00000625 0.79 SHOPIFY A NPV 0.79 CANADIAN PACIFIC RAILWAY NPV 0.77 VINCI EUR2.5 0.77 LONDON STK EXCHANGE GRP GBP0.06918605 0.76 SMURFIT KAPPA GRP EUR0.001 0.76 UNITEDHEALTH GRP USD0.01 0.75 PEPSICO USD0.017 0.74 MONDELEZ INTL USD0.01 0.74 PEARSON GBP0.25 0.70 NINTENDO CO NPV 0.69 LVMH MOET HENNESSY LOUIS VUI EUR0.3 0.68 VH GBL SUSTAINABLE ENERGY NPV 0.67 MOODYS CORP USD0.01 0.67 CRH EUR0.32 0.66 FISERV USD0.01 0.66 LAM RESEARCH CORP COM USD0.001 0.65 BREEDON GRP NPV 0.64 FLUTTER ENT GBP0.09 0.63 SHISEIDO CO NPV 0.63 COOPER COS COM USD0.10 0.63 MASTERCARD A USD0.0001 0.62 MERCADOLIBRE COM USD0.001 0.61 BECTON DICKINSON & CO USD1 0.59 SAFRAN EUR0.20 0.58 ILLUMINA COM USD0.01 0.58 PRYSMIAN EUR NPV 0.57 BAXTER INTL COM USD1 0.56 DELTA AIR LINES USD0.0001 0.55 APPLIED MATERIALS USD0.01 0.55 STRYKER CORP USD0.1 0.54 HARGREAVES LANSDOWN GBP0.004 0.54 SONIC HEALTHCARE NPV 0.53 ADYEN NPV 0.53 CATALENT USD0.01 0.52 WEST PHARMACEUTICAL SERV USD0.25 0.51 INTERCONTINENTAL EXCHANGE GRP USD0.01 0.50 KAO CORP NPV 0.50 TAIWAN SEMICONDUCTOR MANUFACTURING TWD10 0.48 EBAY USD0.001 0.48 REMY COINTREAU EUR1.6 0.48 Please see the disclaimer at the end of this document.
    [Show full text]
  • THE MONTHLY January 2019
    THE MONTHLY January 2019 FJanuary 2019 Table of contents About our January feature article ...................................................................................... 3 Hardman & Co Healthcare Index ....................................................................................... 3 Review of 2018 ...................................................................................................................... 4 Movers and shakers ............................................................................................................... 6 About the authors .............................................................................................................. 10 Company research ............................................................................................................. 11 1pm plc ................................................................................................................................... 12 Advanced Oncotherapy ..................................................................................................... 13 Allergy Therapeutics ........................................................................................................... 14 Alliance Pharma .................................................................................................................... 15 Arbuthnot Banking Group ................................................................................................. 16 Avatca ....................................................................................................................................
    [Show full text]
  • Gene Therapy Is
    Gene therapy is now Annual report and accounts 2017 Oxford BioMedica in brief Oxford BioMedica is a pioneer of gene and cell therapy with a leading position in lentiviral vector and cell therapy research, development and bioprocessing. Gene and cell therapy is the treatment of disease by the delivery of therapeutic DNA into a patient’s cells. This can be achieved either in vivo (referred to as gene therapy) or ex vivo (referred to as cell therapy), the latter being where the patient's cells are genetically modified outside the body before being re-infused. Oxford BioMedica is focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GlaxoSmithKline, Bioverativ, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 300 people. Introducing Oxford BioMedica 1 At the front and centre 3 Multi-billion $ market sector 3 Targeting unmet needs 4 Enabling new treatments 4 Sharing
    [Show full text]
  • Skyepharma PLC PLC Skyepharma Skyepharma
    SkyePharma PLC SkyePharma PLC SkyePharma Making good drugs better Annual Report and Accounts 2009 Registered Head Office Annual Report and Accounts 2009 105 Piccadilly London W1J 7NJ Registered No: 107582 Telephone: +44 (0)207 491 1777 Fax: +44 (0)207 491 3338 Email: [email protected] Web: www.skyepharma.com www.skyepharma.com Making good drugs better Advisers Auditors Depositary Bankers Ernst & Young LLP Bank of New York Mellon HSBC Bank plc Apex Plaza 101 Barclay Street 70 Pall Mall Reading New York NY 10286 London RG1 1YE USA SW1 5EZ Solicitors Joint Corporate Brokers Registrars Fasken Martineau LLP & Financial Advisers Capita Registrars 17 Hanover Square Credit Suisse Northern House London 20 Columbus Courtyard Woodsome Park W1S 1HU London Fenay Bridge E14 4DA Huddersfield Clifford Chance LLP West Yorkshire Welcome to 10 Upper Bank Street Piper Jaffray Ltd HD8 0GA London One South Place E14 5JJ London SkyePharma PLC EC2M 2BR SkyePharma’s mission is to become one of the world’s leading speciality drug delivery companies, powered WARNING TO SHAREHOLDERS – BOILER ROOM SCAMS through excellence in its oral and inhalation technologies. Over the last year, many companies have become aware that their shareholders have received unsolicited phone calls or SkyePharma strives to deliver clinical benefits for patients correspondence concerning investment matters. These are typically from overseas based “brokers”who target UK shareholders, offering to sell them what often turn out to be worthless or high risk shares in US or UK investments. These operations are commonly known as by using its multiple delivery technologies to create “boiler rooms ”. These “brokers”can be very persistent and extremely persuasive, and a 2006 survey by the Financial Services Authority (FSA) has reported that the average amount lost by investors is around £20,000.
    [Show full text]
  • FTSE Factsheet
    FTSE COMPANY REPORT Share price analysis relative to sector and index performance Benchmark Holdings BMK Pharmaceuticals and Biotechnology — GBP 0.605 at close 14 May 2021 Absolute Relative to FTSE UK All-Share Sector Relative to FTSE UK All-Share Index PERFORMANCE 14-May-2021 14-May-2021 14-May-2021 0.7 300 190 1D WTD MTD YTD 0.65 180 Absolute 0.8 1.7 -5.5 -4.7 Rel.Sector 0.2 0.6 -6.9 -9.5 250 170 0.6 Rel.Market -0.3 3.1 -6.1 -12.8 160 0.55 200 150 VALUATION 0.5 140 0.45 Trailing Relative Price Relative Relative Price Relative 150 130 0.4 PE -ve 120 Absolute Price (local (local currency) AbsolutePrice EV/EBITDA 22.3 0.35 100 110 PB 1.5 0.3 100 PCF -ve 0.25 50 90 Div Yield 0.0 May-2020 Aug-2020 Nov-2020 Feb-2021 May-2021 May-2020 Aug-2020 Nov-2020 Feb-2021 May-2021 May-2020 Aug-2020 Nov-2020 Feb-2021 May-2021 Price/Sales 4.0 Absolute Price 4-wk mov.avg. 13-wk mov.avg. Relative Price 4-wk mov.avg. 13-wk mov.avg. Relative Price 4-wk mov.avg. 13-wk mov.avg. Net Debt/Equity 0.4 100 90 90 Div Payout 0.0 90 80 80 ROE -ve 80 70 70 70 Index) Share Share Sector) Share - - 60 60 60 DESCRIPTION 50 50 50 The Company is an international animal health, 40 40 40 RSI RSI (Absolute) technical publishing and sustainability business.
    [Show full text]
  • Building the Future
    Building the future Annual report and accounts 2018 Oxford Biomedica in brief The arrival of gene and cell therapy is clear. 1 Oxford Biomedica is a pioneer of gene and cell therapy with a leading Landmark regulatory approvals of these position in lentiviral vector research, development and bioprocessing. Gene and cell therapy is the treatment of disease by the delivery of life-changing treatments are now happening, therapeutic DNA into a patient’s cells. This can be achieved either in vivo and include the very first commercial use of (referred to as gene therapy) or ex vivo (referred to as cell therapy), Oxford Biomedica’s LentiVector® technology. the latter being where the patient’s cells are genetically modified outside the body before being re-infused. Our science is now a therapeutic reality for Oxford Biomedica is focused on developing life changing treatments patients suffering from some of the most serious for serious diseases. Oxford Biomedica and its subsidiaries (the “Group“) diseases. What we are witnessing is just the Introducing Oxford Biomedica have built a sector leading lentiviral vector delivery platform, LentiVector, which the Group leverages to develop in vivo and ex vivo products beginning... both in-house and with partners. The Group has created a valuable ——— proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products.
    [Show full text]